CloneID: Lym-1
Heavy Chain modification: Fc Silent™
Antigen Long Description: The original antibody was generated by immunizing mice with tumor cell nuclei preparations as immunogens.
Buffer Composition: PBS with 0.02% Proclin 300.
Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7
Uniprot Accession No.: P04233
Specificity Statement: This antibody has high affinity for a discontinuous epitope on the β subunit of the human HLA-DR10 surface membrane antigen of malignant B cells, which is not expressed on normal lymphocytes. HLA-DR10 (DR10) is a HLA-DR serotype that recognizes the DRB1*1001 gene product.
Application Notes (Clone): This antibody could recognize cell lines of B-cell lineage but not cells of T-cell, myeloid, or erythroid derivation in a live cell radioimmunoassay. Flow cytometric analysis of 22 lymphoma biopsies showed that the majority of B-cell tumors were LYM-1 positive. Approximately 40% of B-cell chronic lymphocytic leukemias were found to be positive with Lym-1. The binding of this antibody to peripheral blot lymphocytes was assessed using indirect immunofluorescence staining. Immunoperoxidase staining of nonlymphoid human organs and tissues revealed weak reactivity of Lym-1. This antibody was also capable of immunoprecipitating HLA-DR10 antigen from Raji cells and ARH-77 myeloma cells. (PMID: 3542194). This antibody also was used for immunohistochemical staining of advanced B-cell NHL tissues from patients (PMID: 10809213). This antibody can be used to identify the HLA-DR variant HLA-DR10 in a western blot (PMID: 8917632). LYM-1 chimeric antigen receptor T cells were demonstrated to exhibit potent anti-tumor effects against B-cell lymphoma (PMID: 29261129).
English
Deutsch
